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Comparison of small extracellular vesicles isolated from plasma by
ultracentrifugation or size-exclusion chromatography: yield, purity and
functional potential
Kaloyan Takov , Derek M. Yellon and Sean M. Davidson
The Hatter Cardiovascular Institute, University College London, London, UK
ABSTRACT
Interest in small extracellular vesicles (sEVs) as functional carriers of proteins and nucleic acids is
growing continuously. There are large numbers of sEVs in the blood, but lack of standardised
methods for sEV isolation greatly limits our ability to study them. In this report, we use rat plasma
to systematically compare two commonly used techniques for isolation of sEVs: ultracentrifuga-
tion (UC-sEVs) and size-exclusion chromatography (SEC-sEVs). SEC-sEVs had higher particle num-
ber, protein content, particle/protein ratios and sEV marker signal than UC-sEVs. However, SEC-
sEVs also contained greater amounts of APOB+ lipoproteins and large quantities of non-sEV
protein. sEV marker signal correlated very well with both particle number and protein content
in UC-sEVs but not in all of the SEC-sEV fractions. Functionally, both UC-sEVs and SEC-sEVs isolates
contained a variety of proangiogenic factors (with endothelin-1 being the most abundant) and
stimulated migration of endothelial cells. However, there was no evident correlation between the
promigratory potential and the quantity of sEVs added, indicating that non-vesicular co-isolates
may contribute to the promigratory effects. Overall, our findings suggest that UC provides plasma
sEVs of lower yields, but markedly higher purity compared to SEC. Furthermore, we show that the
functional activity of sEVs can depend on the isolation method used and does not solely reflect
the sEV quantity. These findings are of importance when working with sEVs isolated from plasma-
or serum-containing conditioned medium.
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Introduction
Extracellular vesicles (EVs) comprise a diverse population
of nano- andmicroparticles released into the extracellular
space by living cells and serving as paracrine, endocrine
or autocrine signals [1,2]. Small EVs (sEVs), such as
exosomes, have characteristic tetraspanin membrane
markers (CD9, CD63, CD81) [3], are of predominantly
endosomal origin [4–7] and have been shown to carry
various proteins and nucleic acids [8–12].
EVs present in the blood have attracted the most
interest as novel biomarkers for cancer, kidney, cardio-
vascular and neurodegenerative diseases [13] and they
have also been shown to be functionally active, e.g. med-
iating cardioprotection [7,14–16], angiogenesis [17,18]
and coagulation [19,20]. Blood plasma or serum sEVs
can be isolated in large numbers [21,22] but ample evi-
dence exists for the presence of a high degree of contami-
nants in vesicle isolates including non-EV proteins
[22,23] and lipoproteins [21,24,25], regardless of the iso-
lation method used [22,24,26,27]. Co-purification arises
from similarities in size and/or density of the isolated
sEVs and the co-existing lipoproteins or protein aggre-
gates [28] or due to their physical association [23,24,28].
Despite the existence of multiple reports which compare
sEV isolation methods [21–23,25,29–32], there is cur-
rently no agreement on an optimal technique to yield
high-purity sEVs from blood.
In some cases, the non-EV protein contamination in
vesicle samples obtained from plasma- or serum-con-
taining fluids can be so extensive that specific sEV
markers may even become undetectable in the isolates
[25,31,33]. Additionally, in nearly 50% of the published
experiments in which sEVs were isolated from cell
culture-conditioned medium, the cells had been cul-
tured in the presence of serum [34]. Considering that
there are enormous numbers of lipoprotein particles in
plasma and serum (~1016/ml) [28], this may result in a
marked lipoprotein contamination in downstream
experiments. It is therefore crucial to directly compare
methods for sEV isolation in relation to contamination
by both soluble protein and lipoproteins.
Ultracentrifugation (UC) is one of themost commonly
used methods in the field [6,34], but reportedly leads to
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co-purification of lipoproteins [24] and soluble protein
[23,25] with plasma sEVs. Instead, size-exclusion chro-
matography (SEC) has been proposed to provide sEVs
with high purity [21,23,35,36] and higher functionality
[31]. This is despite the fact that some lipoprotein classes
(i.e. APOB+ lipoproteins) are known to co-isolate in large
numbers with sEVs when using SEC [21,24,37,38].
Performing direct comparison of different techniques, e.
g. UC versus SEC, is vital in order to establish an optimal
method for plasma sEV isolation and to understand
plasma sEVs characteristics.
The endothelium is the only organ in direct contact
with blood and its diverse populations of sEVs. It is
therefore of interest to determine the effect that plasma
sEVs have on its function. It has been reported that
EVs isolated from serum of healthy humans can acti-
vate endothelial cells and exhibit proangiogenic func-
tions in vitro and in vivo [17,18]. Furthermore,
erythrocyte, platelet and leukocyte EVs have all been
shown to stimulate an angiogenic response (reviewed
in Ref. [39]). However, there are no reports that com-
bine a comparison of yield, purity and functional activ-
ity of plasma sEVs.
In this study, we compared sEVs isolated using the
“gold standard”, UC (UC-sEVs) [6] or the increasingly
popular technique of SEC (SEC-sEVs) [35], and analysed
their yield, purity and promigratory effects on endothe-
lial cells. We demonstrated that, despite a greater yield of
SEC-sEVs, their purity is compromised when compared
to UC-sEVs. We further showed that, while normalisa-
tion of sEVs to particle number or protein content is
appropriate for UC-sEVs, this does not accurately repre-
sent the sEV content of all fractions from a SEC isolation.
Plasma sEV isolates contained proangiogenic factors and
promoted endothelial cell migration, but no correlation
was found between migration levels and administered
sEV content indicating that contaminating factors may
also play a role in controlling the observed outcome.
Thus, plasma sEVs obtained by UC appear to be of
superior purity to those isolated by SEC while the choice
of isolation method may strongly impact subsequent
functional experiments.
Materials and methods
Ethical approval
All procedures contained within the application were
approved by the Animal Welfare and Ethical Review
Body (AWERB) and were conducted within the terms of
the UK Home Office Guide on the Operation of Animals
(Scientific Procedures) Act 1986, under Project Licence
number PPL 70/8556 (“Protection of the Ischaemic and
Reperfused Myocardium”). The investigation conforms to
the guidelines fromDirective 2010/63/EU of the European
Parliament on the protection of animals used for scientific
purposes or the NIH guidelines.
Cell culture: human umbilical vein endothelial cells
(HUVECs)
HUVECs were obtained from Lonza (Basel, Switzerland)
as a pooled donor sample (C2519A). Cells were main-
tained in
monolayers in Endothelial Cell Basal Medium 2 (C-
22211, PromoCell, Heidelberg, Germany) supplemented
with Endothelial Cell Growth Medium 2
SupplementPack (C-39211, PromoCell) in a conven-
tional tissue culture incubator at 37°C/5% CO2. Cells
were passaged using TrypLE Express Enzyme
(12605028, ThermoFisher, Dartford, UK).
Preparation of plasma or serum for UC or SEC
Male Sprague-Dawley rats (300–400 g) were obtained
from Charles River (Margate, UK). Food and water
were provided ad libitum. Blood sampling was performed
at random times of the day. Rats were anaesthetised with
250 mg/kg pentobarbital. Thoracotomy was performed,
and blood was collected from inferior vena cava in syr-
inges pre-filled with citrate buffer (final concentration of
~15mM after dilution with blood). No visible haemolysis
was observed. Blood samples were centrifuged at 1600 g
for 15min, room temperature to remove cells. The super-
natant plasma was transferred to new Eppendorf tubes
and centrifuged at 10,000 g for 30min, room temperature
to remove debris and large vesicles. Plasma samples were
used immediately or frozen at −80ºC.
Isolation of plasma sEVs using UC
One millilitre (for characterisation experiments) or
4 ml (for functional experiments) plasma aliquot was
diluted with PBS (Ca2+-free, Mg2+-free, 14190144,
ThermoFisher) to ~7–8 ml and ultracentrifuged for
70 min at 100,000 g, 4ºC to pellet the sEVs (polycar-
bonate tubes, 355630, Beckman Coulter, Brea, USA;
MLA-55 rotor, Optima MAX-XP, Beckman Coulter)
according to Théry et al. [6]. Supernatant was dis-
carded and sEVs were resuspended in PBS (~7–8 ml)
for washing. A second UC run was performed for
70 min at 100,000 g, 4ºC. The sEV-rich pellet was
resuspended to a final volume of 100–200 µl with
PBS and frozen at −80ºC.
2 K. TAKOV ET AL.
Isolation of plasma sEVs using SEC
Commercially available qEVoriginal SEC columns (iZON
Science, Oxford, UK) were used to fractionate blood
plasma according to the manufacturer’s protocol [35].
One millilitre plasma aliquot was loaded on an SEC
column and 0.5 ml fractions were collected as indicated
(PBS used as eluent) and stored at −80°C. Formaximising
yield for functional experiments, sEV fractions 3.5–6.0 ml
were pooled and concentrated using Vivaspin-4 filter
(100 kDa, polyethersulfone membrane; Sartorius,
Epsom, UK).
Nanoparticle tracking analysis (NTA)
NTA was performed on a NanoSight LM10-HS instru-
ment (NanoSight, Malvern, UK) using Violet (488 nm)
laser module and NTA 3.1 software version. Particle
concentration and size was determined following gen-
eral recommendations [40] adapted to the type of
samples in our studies. A syringe pump with constant
flow injection was used and three videos of 30 s were
captured with Camera Level of 15 and Detection
Threshold of 4.
Protein and nucleic acid content
BCA protein assay kit for low concentrations (ab207002,
Abcam, Cambridge, UK) was used to quantify the protein
content. The assay was performed according to the man-
ufacturer’s instructions. The sample volumes used were
2–60 µl in final reaction volumes of 300 µl. The reactions
were incubated for 120min at 37°C. Absorbance was read
at 562 nm on a FLUOstar plate reader (BMG Labtech,
Aylesbury, UK). Protein concentrations were calculated
using bovine serum albumin (BSA) standards and a four-
parameter logistic curve.
Absorbance at 260 and 280 nm of early SEC frac-
tions was also analysed using LVis plate and FLUOstar
plate reader (BMG Labtech) to confirm the presence of
nucleic acids and protein, respectively.
Dissociation-enhanced lanthanide fluorescence
immunoassay (DELFIA)
Specific markers of sEVs and lipoproteins were quantified
using a previously described DELFIA [21,37] with mod-
ifications. Samples were added to a high-binding 96-well
microplate (DY990, R&D Systems, Abingdon, UK). After
overnight incubation at 4°C, blocking with 1% BSA/PBS
for 1 h at room temperature was performed. This was
followed by primary antibody incubation at 1 μg/ml in
PBS for 2 h at room temperature (CD9: CloneM-L13, BD
Biosciences, San Jose, USA; CD81: Clone JS-81, BD
Biosciences; HSP70: Clone N27F3-4, Santa Cruz
Biotechnology, Santa Cruz, USA; APOB: Clone H-300,
Santa Cruz Biotechnology) and secondary antibody incu-
bation at 0.25 µg/ml in PBS for 1 h at room temperature
(biotin-conjugated goat anti-rabbit IgG for APOB,
ab97073, Abcam or biotin-conjugated goat anti-mouse
IgG1 for CD9, CD81 and HSP70, ab98691, Abcam).
1:1000 Eu-labelled streptavidin in DELFIA Assay Buffer
(PerkinElmer, Beaconsfield, UK) was then added and
incubated for 1 h at room temperature. Finally, 100 µl
DELFIA Enhancement Solution (PerkinElmer) was
added to each well and time-resolved fluorimetry was
performed using a PHERAstar plate reader (BMG
Labtech) with excitation at 337 nm, detection at
620 nm, integration start at 60 µs and integration time
of 200 µs. Results are presented as arbitrary units (AU).
Wes™ simple western
The presence of HSP70 and APOB in the isolates was
confirmed using Wes™ Simple Western apparatus
(ProteinSimple, San Jose, USA). ~0.4–0.6 µg protein was
denatured using manufacturer-provided buffer (DTT
based) and loaded in Wes™ multiwell plates. Protein
separation, antibody binding and detection were per-
formed using capillary cartridge separation and following
manufacturer’s instructions. The following primary anti-
bodies were used: HSP70 (at 10 μg/ml; clone N27F3-4,
Santa Cruz Biotechnology), APOB (at 20 μg/ml; clone H-
300, Santa Cruz Biotechnology) and alpha-Actinin-4 (at
32 μg/ml; clone C2C3, GeneTex, Irvine, USA). Anti-
mouse (for HSP70; 042–205, ProteinSimple) and anti-
rabbit (for APOB and alpha-Actinin-4; 042–205,
ProteinSimple) secondary antibodies conjugated to
horseradish peroxidase were used according to the man-
ufacturer’s instructions. Images were obtained and ana-
lysed using Compass software for Simple Western
(ProteinSimple).
Protein arrays
Angiogenic factor profiling of UC-sEVs and SEC-sEVs
was performed using Proteome Profiler Human
Angiogenesis Array (ARY007; R&D Systems) following
manufacturer’s instructions with some modifications.
Each membrane was incubated with ~20 µg protein of
UC-sEVs or SEC-sEVs (from functional experiments).
Prior to incubation, sEVs were lysed with addition of
0.1% (v/v) Triton X-100 and vortexing for 30 s [41].
Streptavidin-DyLight 800 conjugate was used for detec-
tion of biotin-conjugated antibodies at 250 ng/ml
(21,851, ThermoFisher). Membranes were imaged, and
pixel densities were quantified on Odyssey system. The
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spot coordinates can be found on https://resources.
rndsystems.com/pdfs/datasheets/ary007.pdf. Duplicate
spot pixel densities were normalised to Reference
Control spots and presented as relative pixel densities.
Transmission electron microscopy (TEM)
TEM was performed by sEV labelling using 0.5% ura-
nyl acetate following previously published protocols
with modifications [6]. Briefly, ~2 µl of each sample
(0.12–0.16 µg for samples containing high number of
sEVs) was adsorbed on Formvar-carbon electron
microscopy grids. After washing with H2O, the grids
were transferred to a drop of uranyl acetate solution,
pH 7 for ~3 min. Excess fluid was blotted, and the grids
were imaged using a Jeol 1010 electron microscope
(Jeol Ltd, Peabody, USA).
EV-TRACK
The relevant data were submitted to the EV-TRACK
knowledgebase (EV-TRACK ID: EV180051) [42].
Endothelial cell migration
A modified Boyden’s chamber assay was performed to
assess for promigratory functions of plasma sEV iso-
lates on HUVECs following manufacturer’s instruc-
tions with some modifications (NeuroProbe,
Gaithersburg, USA). Bottom wells of a 12-well
NeuroProbe chemotaxis chamber (AA12,
NeuroProbe) were filled with vehicle (PBS), 10% FBS
(positive control) and SEC- or UC-isolated sEVs as
indicated (n = 5). Eight micrometres polycarbonate
track-etch membranes (PFB8, NeuroProbe) were used
as filters for HUVEC migration. Thirty-thousand
HUVECs/well in Endothelial Serum-Free Defined
Medium (Cell Applications Inc, San Diego, USA;
113–500, Sigma) were plated in the top wells and the
chamber was incubated for 6 h at 37°C, 5% CO2. At the
end of the incubation period, membranes were col-
lected, and the top side was scraped to remove non-
migrated cells. Membranes were fixed in 100% cold
methanol, stained using 0.5 % (w/v) Crystal Violet
solution and scanned using CanoScan LiDE 220 scan-
ner (Cannon). ImageJ was used to quantify the total
staining intensity of each well. Intensities were mea-
sured for duplicate wells and normalised to the positive
control (10% FBS). Representative images of each
group were acquired on Nikon Eclipse TE200 inverted
microscope (Nikon).
Statistical analysis
Data are plotted as mean ± SEM. GraphPad Prism was
used for statistical analyses and graph production
(GraphPad Software, San Diego, USA). Pearson’s or
Spearman’s correlation tests were performed where
indicated after a Kolmogorov-Smirnov test for normal-
ity. Statistical comparisons were performed using
Student’s t-tests or one-way ANOVA with Tukey’s
post-hoc test as indicated. p value of < 0.05 was con-
sidered significant.
Results
Particle and protein content of plasma sEV samples
isolated by UC or SEC
Platelet-free plasma was isolated from the blood of rats
in accordance with published recommendations
[26,43]. In order to directly compare protein and par-
ticle yields, equal volumes of blood plasma collected
from the same animal were processed using differential
UC [6] or commercially available SEC columns (qEV,
iZON) (Supplementary Figure 1(a)).
Pilot SEC experiments (Supplementary Figure 1(b))
and our previous studies [37] indicated that sEVs from
plasma samples eluted with a peak in SEC fractions
~5–6 ml while the bulk of protein appeared at ~10 ml.
Hence, subsequently, fractions of 3.5–7.5 ml from SEC
were collected and analysed. As expected, protein con-
tent gradually increased with each fraction (Figure 1
(a)). Strikingly, the number of particles also followed a
similar pattern without an obvious early peak (5–6 ml)
as measured by NTA (Figure 1(b)). The ratio of the
number of particles to the protein content (particle/
protein ratio) has previously been suggested to be an
adequate marker of sEV purity [22]. This value peaked
at SEC fractions 5.0–5.5 ml (Figure 1(c)) indicative of
an enrichment of particles relative to protein in these
fractions. Therefore, these fractions were subsequently
referred to as “SEC-peak”.
The particle content of the UC samples was negli-
gible compared to SEC-peak, and protein content and
particle/protein ratios were also lower in UC samples
than SEC-peak fractions (Figure 1(a–c)). Although the
size distribution of particles in the SEC-peak and UC
samples appeared similar (Figure 1(d)), particle modal
size in the UC samples was significantly higher than
SEC-peak (UC: 96.6 ± 3.1 nm vs SEC-peak:
81.5 ± 3.3 nm, p < 0.05; Figure 1(e)).
Overall, based on protein content and particle size
distribution analysis, a higher particle yield and greater
apparent purity, based on particle/protein ratios, is
achieved with SEC compared to UC.
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Figure 1. Protein and particle content in samples obtained from rat blood plasma using size exclusion chromatography (SEC) or
ultracentrifugation (UC).
Protein content was measured by BCA assay and particle concentration and size by NTA. (a): Protein amount in SEC fractions 3.5–7.5 ml and UC
samples. n = 6. (b): Particle number in SEC fractions 3.5–7.5 ml and UC samples. n = 6. (c): Particle/protein ratio for SEC fractions 3.5–7.5 ml and UC
samples. n = 6. (d): Particle size distribution for SEC fractions 5.0–5.5 ml and UC demonstrates the presence of particles in the typical sEV range. SEC
fractions 5.0 and 5.5 ml were used due to their high particle/protein ratio. n = 6–12, curve shows mean values. (e): Modal size of the particles
isolated from SEC (5.0–5.5 ml) and UC. *p < 0.05; Student’s t-test. n = 6–12.
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Characterisation of sEV content and purity of UC
and SEC samples
Particle number and protein content are not sufficient
to completely understand sEV yield and purity, since
NTA does not distinguish between sEVs and similarly
sized molecules such as small lipoproteins. To address
this issue, we used DELFIA (a high-sensitivity immu-
noassay [21,37]), to analyse content of sEVs markers
(CD81 and HSP70) [3,14,44] and contaminant lipopro-
teins (APOB) [24,28,31].
Large quantities of CD81 and HSP70 were detected
in SEC fractions 5.0–6.5 ml (with a clear peak at 5.5 ml;
Figure 2(a–c)), suggestive of high sEV content. Nucleic
acid and protein content can be determined by mea-
suring the samples’ absorbance at 260 and 280 nm,
respectively. This confirmed the presence of an early
peak at 5.5 ml for both A260 and A280 coinciding with
the CD81 and HSP70 peaks (Figure 2(d,e)). UC sam-
ples contained CD81+ and HSP70+ particles, but the
yield was only ~25% of the combined sEV-containing
SEC fraction yield (Figure 2(a–c)). The performance of
SEC columns was found to be highly consistent
between experiments (Supplementary Figure 2) and a
strong positive correlation between CD81 and HSP70
signal in individual sEV isolates was found (p < 0.001),
confirming the efficient isolation of vesicles positive for
both CD81 and HSP70 (Figure 2(f)). Interestingly,
despite the lower content of particles and CD81 and
HSP70 markers in UC isolates (Figure 1(b,c), 2(c)), the
sEV marker/total protein ratio was generally higher for
UC samples compared to peak sEV SEC fractions
(Figure 2(g); also confirmed using pooled SEC frac-
tions: see Figure 8(e)).
Next, we compared the degree of contamination with
APOB+ lipoproteins when using the two techniques.
APOB+ lipoproteins were detected in the sEV isolates of
both techniques but levels in the peak sEV SEC fractions
(5.0–6.0ml) were markedly higher indicative of substantial
lipoprotein contamination in SEC isolates (Figure 3(a)).
Moreover, normalisation of APOB signal to protein con-
tent showed a striking ~30 times greater quantity of APOB
in the peak sEV fraction of SEC (5.5 ml) compared to the
UC samples (Figure 3(b)). Pooling and concentrating the
peak sEV fractions of SEC resulted in a visually opaque
emulsion suggestive of a marked presence of lipids (Figure
3(c)). Additionally, normalisation of APOB signal to CD81
content, as an estimate of sEV purity from lipoproteins,
also demonstrated almost 60 times higher APOB/CD81
ratio in the peak sEV fraction of SEC (5.5 ml) compared to
the UC samples (Figure 4).
Collectively, these data indicate that SEC resulted in
a higher yield of sEVs but with marked contamination
by soluble protein and lipoproteins. The key data on
yield and purity are summarised on Figure 4.
Western blotting confirmed the results obtained
with DELFIA (Figure 5(a)). The sEV marker HSP70
was more abundant in UC-sEVs while the lipoprotein
marker APOB was markedly higher in pooled SEC-
sEVs (Figure 5(a)). As expected, alpha-Actinin-4 (a
marker of large- and medium-sized EVs [3]) was vir-
tually absent in the sEV isolates while it was present in
non-purified plasma (Figure 5(a)).
TEM can be used to confirm the contents of the
isolates. When dried for staining, lipoproteins have a
typical, round white appearance, while EVs take on a
collapsed vesicle or so-called “cup-shaped” appear-
ance [45]. Representative TEM images supported
the nanoparticle tracking and immunoassay data
obtained for both UC and SEC samples (Figure 5
(b)). Pre-sEV fractions of SEC contained predomi-
nantly larger, round, lipoproteins-like structures,
while the peak sEV fraction 5.5 ml contained sEVs
in addition to many particles resembling lipoproteins
(Figure 5(b), upper panels). The late, post-sEV frac-
tions comprised mainly of dense protein and lipopro-
tein material (Figure 5(b), upper panels). TEM
images of UC-sEVs showed mostly sEVs with occa-
sional presence of lipoprotein-like particles (Figure 5
(b), lower panels).
Particle and protein content as estimates of sEV
yield
To conduct functional or analytical experiments, sEV
isolates are usually normalised either in terms of equal
particle number or protein concentration. To assess the
ability of these approaches to correctly estimate the
sEV content in plasma isolates, sEV marker content
was plotted against particle number or total protein
concentration. For UC samples, a strong positive cor-
relation was found between particle number and CD81
or HSP70 content (p < 0.001 and p < 0.0001, respec-
tively; Figure 6(a,b)), and between protein concentra-
tion and CD81 or HSP70 content (p < 0.01 and
p < 0.05, respectively; Figure 6(a,b)). Strikingly, how-
ever, particle number or protein content did not posi-
tively correlate with sEV markers for all SEC fractions
(Figure 7(a–c)). Positive associations were found only
in fraction 5.0 ml for particle number and CD81 or
HSP70 content (p < 0.001, Figure 7(a)) and protein
concentration and CD81 or HSP70 content (p < 0.001
and p < 0.01, respectively; Figure 7(a)). Meanwhile,
neither particle number nor protein concentration of
peak sEV SEC fractions 5.5 and 6.0 ml showed a
positive correlation with sEV markers (Figure 7(b,c)).
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Figure 2. sEV content, as determined by the expression of marker proteins, in rat blood plasma samples obtained using SEC or UC.
(a,b): sEV (CD81 – panel (a), HSP70 – panel (b)) markers were measured by DELFIA for SEC fractions 4.0–7.0 ml and UC samples. AU – arbitrary units
normalised to volumes in each sample. n = 6. (c): UC sEV yield presented as a % of combined SEC fractions 5.0–6.5 ml CD81 and HSP70 signal (data
from (a) and (b)). n = 6. (d,e): Absorbance of SEC samples at 260 nm (A260), representing relative nucleic acid concentrations; and at 280 nm (A280),
representing relative protein concentrations. Note the presence of early peaks at both A260 and A280 which coincide with the CD81 and HSP70
marker signal peaks (data from panels (a) and (b), dashed lines). n = 6. (f): Correlation between HSP70 and CD81 signal. SEC fractions 4.0–7.0 ml
and UC samples included. p < 0.0001; Spearman’s correlation test, Spearman r = 0.958. n = 48. (g): sEV marker signal (from panels (a) and (b)) was
normalised to total protein amount for the peak sEV SEC fractions 5.0–6.0 ml as well as for the UC samples. n = 6.
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Overall, estimation of the amount of isolated plasma
sEVs by total protein content or particle number is
appropriate for UC-isolated sEVs and some fractions
of the SEC-isolated sEVs but may not be a suitable
approach for all peak sEV-SEC fractions.
Comparison of the UC-sEVs and SEC-sEVs function
using an endothelial cell migration assay
For functional analysis, sEVs from different samples
can be normalised either by particle number, protein
content or sEV marker content. We investigated
whether these different methods can influence results
in an endothelial cell migration assay.
sEV yield was maximised for functional experiments
using larger starting plasma volume for UC or concen-
tration of sEV-containing fractions for SEC. Particle,
protein, lipoprotein and sEV marker data were in accor-
dance with Figures 1–3 (Figure 8(a–e)).
For functional studies, Boyden’s Chamber migration
experiments were conducted with endothelial cells
(HUVECs). Administration of UC-sEV stimulated
HUVECmigration (Figure 9(a,b)). An equivalent particle
number of SEC-sEVs promoted migration of endothelial
Figure 3. Lipoprotein content in samples of rat blood plasma obtained with SEC or UC.
(a): APOB as a marker of lipoproteins measured by DELFIA for SEC fractions 4.0–7.0 ml and UC samples. AU – arbitrary units normalised to volumes
in each sample. n = 6. (b): APOB lipoprotein marker signal was normalised to total protein amount for the peak sEV SEC fractions 5.0–6.0 ml as well
as for the UC samples. n = 6. (c): UC sample visual appearance compared to pooled and concentrated SEC fractions 3.5–6.0 ml. Note the opaque
appearance of the SEC sample indicative of the presence of lipids.
Figure 4. Summary of yield and purity of sEVs isolated by SEC or UC.
Summarised key points from Figures 1 to 3. sEV yield (left panel, see Figure 2(a)), protein contamination (middle panel, see Figure 2(g)) and
lipoprotein contamination (right panel, see Figures 2(a) and 3(a) shown for the peak sEV fractions (5.0, 5.5 and 6.0 ml) of SEC and UC samples. CD81
signal was used as an estimate of sEV content.
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cells to a similar degree (Figure 9(a,b)) despite the CD81
signal being ~11 times lower in SEC samples (Figure 8(d,
e)). Interestingly, loading much higher particle numbers
of SEC-sEVs, so as to match the CD81 signal of the UC-
sEVs, led to only a fairly small, non-significant increase in
HUVEC migration (Figure 9(a,b)). Finally, equalising
SEC-sEVs based on protein concentration produced a
significantly higher migration with SEC-sEVs despite
there being approximately three times less CD81
(Figures 8(d,e), 9(a,b)).
To obtain a preliminary profile of angiogenic factors
present in the plasma sEV samples which may be respon-
sible for the promigratory effects, protein arrays were
used. Approximately twenty micrograms protein of
SEC-sEVs or UC-sEVs were incubated on protein array
membranes (Figure 10(a)). Multiple potential promigra-
tory factors were found to be present in the sEV isolates
with the most abundant one being endothelin-1, a known
stimulator of endothelial cell migration [46,47] (Figure 10
(a,b)). Further studies will be required for precise identi-
fication of the factor(s) and downstream mechanisms
responsible for promigratory effects of plasma sEVs on
endothelial cells.
Overall, our data showed that plasma sEVs pro-
mote migration of endothelial cells but normalisation
of sEV samples to particle number, protein content
or sEV marker content can lead to dramatically dif-
ferent functional outcomes. Protein profiling identi-
fied multiple candidates which may be responsible
for the observed effects with endothelin-1 being the
most abundant proangiogenic factor present in sEV
isolates. We also observed a lack of direct association
between the extent of endothelial cell migration and
added sEVs indicating that the effect of the isolates
may be influenced by contaminating, non-vesicular
material.
Figure 5. Western blotting and electron microscopy of rat blood plasma samples obtained with SEC or UC.
(a): Wes™ Simple Western (ProteinSimple; see Methods for details) for APOB (left), HSP70 (right, top), alpha-Actinin-4 (right bottom) of UC and
pooled SEC (3.5–6.0 ml) samples. (b): TEM images of SEC fractions 4.0, 5.5 and 8.0 ml (top panels) and UC-sEVs (bottom panels). Arrows indicate
lipoprotein-resembling structures. Arrowheads indicate sEVs. Scale bar: 200 nm.
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Discussion
In this report, UC and SEC were compared as methods
for purifying sEVs from blood plasma. Higher yields of
sEVs were obtained with SEC, but samples had substan-
tially compromised purity in comparison to UC. Particle
and protein content alone were insufficient to provide an
accurate estimation of sEV content or lipoprotein con-
tamination in a plasma vesicular isolate. This confirmed
the importance of measuring the levels of specific sEV
markers and contaminating factors. APOB content ana-
lysis suggested that contaminating lipoproteins were pre-
sent in excess in the SEC-sEV samples. Furthermore,
sEV marker content relative to total protein was lower
in peak sEV-SEC fractions compared to the UC-sEVs
indicating that soluble protein may also be a contaminat-
ing factor in SEC isolates. Finally, using an endothelial
cell migration assay, we demonstrated that sEV
functional outcomes are dependent on the isolation
method used and effects of blood plasma sEVs may be
obscured by the presence of contaminating factors.
It has been previously argued that a pure population of
1010 sEVs theoretically contains ~1 µg of protein [7].
Other studies have suggested that even higher ratios of
particles per µg of protein have to be present in order to
consider a population of sEVs highly pure [22].
Nevertheless, with plasma or serum isolates, it is virtually
impossible to achieve such purities [22]. Intriguingly, we
found that particle/protein ratio is not an accurate mea-
sure of purity in blood-derived sEV samples. Analysing
SEC isolation as a standalone method showed very high
particle/protein ratios in SEC-sEV fractions, indicative of
high purity. Moreover, when SEC was systematically
compared to UC, particle/protein ratios obtained for
peak sEV fractions from SEC were markedly higher
than UC values suggesting SEC-sEVs are of better purity
Figure 6. Correlation of sEV marker signal and particle or protein concentration of vesicles isolated by UC of rat blood plasma.
Particle (left panels) or protein (right panels) concentration of UC samples plotted against CD81 (a) or HSP70 (b) marker signal. Positive correlations
were found for all four panels ((a): CD81 vs particles: p < 0.001; Pearson’s correlation test, Pearson r = 0.975. CD81 vs protein: p < 0.01; Pearson’s
correlation test, Pearson r = 0.938. (b): HSP70 vs particles: p < 0.0001; Pearson’s correlation test, Pearson r = 0.996. HSP70 vs. protein: p < 0.05;
Pearson’s correlation test, Pearson r = 0.899).
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than UC-sEVs. In contrast, immunoassays for APOB+
lipoproteins and sEV markers indicated the higher parti-
cle number in SEC-sEVs did not represent bona fide
sEVs. Indeed, as previously reported by others, a huge
number of plasma particles detected by NTA are not
sEVs [21]. Overall, taking our data and previous consid-
erations into account, particle/protein ratio is not valid as
a sole indicator for purity of plasma sEV isolates.
Importantly, we showed that total APOB, as amarker of
various lipoproteins [48], is markedly higher in SEC com-
pared to UC samples. These findings are in accordance
with our previous studies [37] and other reports which
have demonstrated that lipoproteins are likely co-isolated
with sEVs when using plasma [21,24,38]. Using
commercially available SEC columns, Sodar et al. showed
that APOB+ events co-purify with sEV marker+ events
[24], while Welton et al. used an in-house prepared SEC
column and also demonstrated co-isolation of APOB+
material with CD9+/CD63+/CD81+ particles [21].
Therefore, the co-purification of APOB+ lipoproteins and
sEVs using SEC is likely to be an inherent property of SEC
as a method for plasma vesicle isolation.
Another indicator of lipoprotein contamination of
SEC-sEVs is the modal size of the particles which was
lower in SEC-sEVs than UC-sEVs. This may be due to
the presence of more, smaller lipoprotein particles in SEC
samples (e.g. APOB+ low-density lipoproteins [24]) which
could reduce the modal size significantly. Notably, an
Figure 7. Correlation of sEV marker signal and particle or protein concentration of vesicles isolated by SEC of rat blood plasma.
Particle (left panels) or protein (right panels) concentration of peak sEV-SEC fractions 5.0 ml (a), 5.5 ml (b) and 6.0 ml (c) plotted against CD81 (top
panels) or HSP70 (bottom panels) marker signal. Positive correlations were found for all four panels in (a) (CD81 vs particles: p < 0.001; Pearson’s
correlation test, Pearson r = 0.983. CD81 vs protein: p < 0.001; Pearson’s correlation test, Pearson r = 0.990. HSP70 vs. particles: p < 0.001; Pearson’s
correlation test, Pearson r = 0. 0.978. HSP70 vs. protein: p < 0.01; Pearson’s correlation test, Pearson r = 0.963). No positive correlations were found
in panels (b) and (c) (p > 0.05; Pearson’s or Spearman’s correlation test as required, except top right panels where CD81 signal and protein
concentration correlated negatively, p < 0.01; Pearson’s correlation test, Pearson r = −0.937 for top right panel in (b) and p < 0.05; Spearman’s
correlation test, Spearman r = −0.943 for top right panel in (c)).
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alternative explanation is that sEVs might be aggregated or
fused after UC due to the high centrifugation speed used
[49]. This might be expected to influence downstream
functional effects but we have previously used UC to iso-
late plasma sEVs and found that they remain functionally
active in being able to protect both primary cardiomyo-
cytes and intact hearts from ischaemia and reperfusion
injury [14], and in this report, we demonstrate that they
promote migration of endothelial cells. This size difference
between SEC-sEVs and UC-sEVs could also be confirmed
using additional methods, e.g. vesicle sizing using TEM
images [50].
In another study using UC and SEC for isolation of
sEVs from rat blood plasma, Baranyai et al. found that
both methods lead to significant protein impurities in the
sEV isolates [23]. It is important to note that authors used
only albumin as a surrogate marker for protein contam-
ination [23], while in this study we used more general
total protein content alongside APOB as marker for lipo-
protein contamination. Additionally, our study has the
advantage of using equal plasma volumes from the same
animal for each UC and SEC biological replicate which
allowed us to directly compare contaminating factors in
the same experiment. In accordance with albumin data in
Figure 8. Characterisation of sEVs isolated by SEC or UC for use in endothelial cell migration experiments.
For SEC isolation of sEVs, 1 ml of plasma was loaded on a SEC column and fractions 4.0–6.0 ml were collected, pooled and concentrated on
Vivaspin-4 ultrafiltration units (100 kDa cut-off). For UC isolation of sEVs, 4 ml of starting plasma volume were used. (a): Protein amount in SEC and
UC samples measured by BCA assay. n = 4. **p < 0.01. (b): Particle number in SEC and UC samples measured by NTA. n = 4. *p < 0.05. (c): sEV (CD9,
CD81, HSP70) and lipoprotein (APOB) markers measured by DELFIA for SEC and UC samples. AU – arbitrary units normalised to volumes in each
sample. n = 4. Note the marker levels were also normalised to starting plasma volumes and represent the yield of sEV and lipoproteins from 1 ml
plasma. (d): Particle/protein ratio for SEC and UC samples. n = 4. **p < 0.01. (e): sEV marker signal normalised to total protein amount for SEC and
UC samples as a measure of purity of sEVs from soluble protein. Note the higher sEV/total protein content in UC samples despite the lower particle
to protein ratio (panel (d)). **p < 0.01 UC CD9 vs. SEC CD9, *p < 0.05 UC CD81 vs. SEC CD81 and ***p < 0.001 UC HSP70 vs. SEC HSP70, Student’s t-
test.
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Baranyai et al. [23], our results indicated that peak sEV
fractions isolated by SEC are likely contaminated with
soluble protein. Interestingly, the direct comparison to
UC demonstrated that this soluble protein is generally
higher for SEC-sEVs than UC-sEVs as shown by normal-
isation of sEV signal to total protein content. This is a
further advantage of UC over SEC for plasma sEV
purification.
Similarly to other authors [21], we found that NTA or
protein content may not be good parameters to estimate
the number of sEVs for most peak sEV SEC fractions.
This is clearly demonstrated by the lack of correlation
between particle number or protein content and CD81 or
HSP70 levels for peak sEV SEC fractions 5.5 ml and
6.0 ml. On the other hand, UC samples and SEC fraction
5.0 ml showed very good positive correlation for CD81 or
HSP70 and particle number or protein content. These
observations suggest that a higher particle number or
protein level correspond to a higher sEV content for
UC samples, but this is not necessary the case for all
SEC fractions from an isolate. Furthermore, the only
fraction from SEC which shows very good association
of increasing particle number or protein content with
higher sEV markers (i.e. 5.0 ml) demonstrates lower
purity from proteins and marked contamination with
lipoproteins. This questions the validity of using these
Figure 9. SEC-sEVs and UC-sEVs promote migration of endothelial cells in vitro.
(a) modified Boyden’s Chamber assay was employed to study HUVEC migration in response to SEC- and UC-isolated sEVs. 1 × 1010 particles/ml were
used for the UC group. SEC-isolated sEVs were adjusted to match the UC sample in terms of particle number (“SEC: equal particles”), CD81 content
(“SEC: equal CD81”) or protein content (“SEC: equal protein”). Vehicle group contained PBS. Relative levels of SEC-sEV dose-response are: “SEC: equal
protein” = ~4× “SEC: equal particles” and “SEC: equal CD81” = ~11× “SEC: equal particles” (a): All groups showed higher HUVEC migration than
Vehicle control (*p < 0.05, UC vs Vehicle; **p < 0.01, SEC: equal particles vs. Vehicle; ***p < 0.001, SEC: equal CD81 vs. Vehicle and SEC: equal
protein vs. Vehicle, one-way repeated measures ANOVA with Tukey’s post-hoc test, n = 5). SEC: equal protein induced more HUVEC migration than
the UC group ($ p < 0.05, one-way repeated measures ANOVA with Tukey’s post-hoc test, n = 5). Data are presented as whole-well staining
intensities normalised to a positive control (10% FBS). (b): Representative microscopy pictures confirming the data shown in (a). Scale bar: 200 µm.
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indices as a means of general normalisation of SEC-sEVs
treatments for functional experiments and indicates that
normalisation parameters should be carefully selected,
and their choice justified.
Other particle enumeration methods may also lead to
similar inaccuracies in the estimation of the actual vesicle
counts (e.g. tuneable resistive pulse sensing is majorly
influenced by lipoproteins [24]). Nevertheless, some
Figure 10. Angiogenic factors present in SEC-sEVs and UC-sEVs isolates.
~20 µg protein of SEC-sEVs or UC-sEVs samples isolated for functional studies (see Figure 6 and Supplementary Figure 3) were incubated on
ARY007 protein array membranes (R&D Systems). Relative levels of 55 angiogenesis-related factors were quantified and presented. (a): Array
membrane images. The red box indicates the most abundant protein – endothelin-1. (b): Quantification of panel (d). Relative pixel densities
represent mean duplicate spot pixel densities normalised to Reference Control spots.
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techniques, such as flow cytometry, may be better able to
distinguish vesicles from contaminants [51].
Other sEV purification techniques may also cause simi-
lar issues when using plasma. For example, there are
reports that density gradient centrifugation is likewise not
able to completely separate sEVs from APOB+ material (i.
e. lipoproteins) [24], while immunocapture of sEVs may
lead to significant contamination with soluble non-sEV
proteins [52]. Thus, a complete separation of sEVs from
contaminants of plasmamay be an arduous task due to the
nature of the plasma samples. A solution can be provided
by the use of multiple isolation techniques in combination
[34,38] which can result in a purer population of sEVs.
However, the yield may be reduced by this approach and
the variability is expected to increase due to the require-
ment of long procedures involving multiple steps. Newer
techniques such as field flow fractionation have been
reported to achieve good separation of sEVs, and appear
promising, but require expensive, specialised equipment,
and are relatively low throughput [44].
Our findings are also relevant for experiments where
sEVs are isolated from serum-supplemented conditioned
medium. As an example, supplementation of medium
with 5% FBS (exosome-depleted) will introduce 2.5 ml
pure serum into 50 ml of conditioned medium. This may
represent a significant problem for SEC-sEV isolations.
Typically, an ultrafiltration step is performed before SEC
of conditioned medium. Ultrafiltration devices (e.g.
Vivaspin, Amicon) concentrate lipoproteins along with
the sEVs and we have previously shown that proteins
lower than the membrane cut-off of the ultrafiltration
units may also be retained [37]. Given the large volumes
of conditioned medium normally used for sEV isolation
[34], purity will be reduced even further and subsequent
analysis will be confounded by the presence of serum-
derived material. We argue that the full potential of SEC
for sEV isolation is only realised when using serum-free
cell culture medium or biological fluids that contain low
levels of lipoproteins and protein, such as urine. In fact, a
recent comparative study showed that UC-sEVs and
SEC-sEVs isolated from serum-free medium conditioned
by cardiomyocyte progenitor cells have similar yields and
purities, but the SEC-sEVs had increase functionality in
terms of activating Erk1/2 in target cells [32]. Similarly,
other reports indicate that higher yields and better purity
EVs can be isolated by SEC of Opti-MEM™ serum-free
medium conditioned by neuroblastoma cells [30].
Therefore, when using serum-free conditions, SEC may
provide vesicles with superior purity than UC.
An alternative method of sEV isolation that is quite
popular due to its simplicity is precipitation. However,
this technique is generally not recommended due to
the very low purity achieved [25,33,45,52]. For
example, in a recent study, the protein content of the
EVs precipitated from 1 ml serum was reported to be
20 mg [18], which is ~20,000 times more than the
theoretical protein contained within 1010 exosomes
[7], and close to the total protein content of serum
(~70 mg/ml [53,54]). Therefore, although these
serum-derived EVs were found to promote endothelial
proliferation, migration and tube-formation [18], their
compromised purity may mask any true EV effects.
A series of functional studies related to angiogenesis
have been performed using EVs derived from vascular
cells or isolated blood cells such as endothelial cells,
platelets, leukocytes and erythrocytes (reviewed in [39]).
Few reports, however, have specifically addressed the
question of whether blood plasma EVs have effects on
angiogenesis [17,18]. In the current study, both UC-sEVs
and SEC-sEVs promoted migration of endothelial cells
and the effects were generally more pronounced with
pooled SEC-sEV samples. Angiogenic factor profiling
indicated that a variety of potential promigratory mole-
cules are contained within the isolates. UC-sEVs and
SEC-sEVs demonstrated very similar profiles with
endothelin-1 being the most abundant proangiogenic
factor in the samples. Endothelin-1 is known to promote
migration and Matrigel invasion of HUVECs, seemingly
through actions on ETB receptor [46]. It also increases
matrix metalloproteinase expression in endothelial cells
and, intriguingly, can have synergistic activities with
other proangiogenic factors such as VEGF [46]. The latter
can be of importance since VEGF was also present in the
sEV samples. Since we also showed that UC-sEVs and
SEC-sEVs could be contaminated with soluble protein,
we cannot exclude the possibility that endothelin-1 or
other potential mediators were co-isolated with the
sEVs rather than being present within them. Future
extensive studies are required to investigate this possibi-
lity, e.g. by western blotting to confirm the presence of
endothelin-1 in the isolates and immunolabelling of sEV
isolates for TEM imaging and confirmation of endothe-
lin-1 presence within the sEVs.
Themain aim of this studywas to specifically address the
question of whether different normalisation approaches
result in discrepant functional outcomes. Intriguingly,
HUVEC migration was not proportional to the quantity
of the administered CD81 indicating that effects may not be
entirely mediated by sEVs. Given the marked contamina-
tion we observed in SEC-sEVs relative to UC-sEVs, we
argue that contaminating factors (either activating or inhi-
biting migration) may play a role. Considering our findings
and the aforementioned studies, determination of the fac-
tors responsible for the promigratory effects and confirma-
tion of their presence within sEVs may be a burdensome
task. Importantly, however, in our study, normalisation of
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UC-sEVs and SEC-sEVs treatments to particle number
provided very similarmigration effects, while normalisation
to total protein content showed significantly higher migra-
tion in SEC-sEV group. This discrepancy in the functional
outcomes may be further complicated by the recovery rates
of sEVs if ultrafiltration units are used to concentrate the
samples [55]. Therefore, we suggest that treatment normal-
isation should be justified, and preferablymultiplematching
including total protein, particle number and sEV-specific
protein content should be performed. Further experimenta-
tion may be useful including dose-response relationships
accounting for the protein, particle or sEV marker content
of UC-sEVs alone and providing reference values for future
studies. Detailed dissection of the effects of single SEC
fractions will also be helpful in determining whether/
which SEC fractions should be pooled for a functional
experiment.
Overall, our findings indicate that UC generally
isolates blood plasma sEVs of better purity com-
pared to SEC, despite a higher yield of sEVs
achieved by SEC. Our functional data on endothe-
lial cell migration suggested that isolation method
can have great impact on functional outcomes. Co-
isolation of soluble protein and lipoproteins with
sEVs when using plasma/serum or other fluids con-
taining blood products may impede interpretation
of experimental findings, and the use of a combina-
tion of isolation techniques may help overcome
these issues.
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